![Restoration of Li+ pathways in the [010] direction during direct regeneration for spent LiFePO4](http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D5EE00641D)
.jpg)
Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy
As other gene editing programs fold or get sold, Arbor Biotechnologies has raised $73.9 million to advance its lead liver-targeting gene therapy into human trials.
As other gene editing programs fold or get sold, Arbor Biotechnologies has raised $73.9 million to advance its lead liver-targeting gene therapy into human trials.
